VERAXA Biotech Receives Positive Regulatory Feedback from Germany for BiTAC®-TCE Development

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced on July 20 that it has received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead BiTAC®-TCE program. The announcement, released on July 23, signals progress as the biotechnology company prepares its most advanced BiTAC®-TCE candidate for future clinical development (https://ibn.fm/zBiDU).

The Scientific Advice procedure allowed VERAXA to consult with regulatory experts before clinical trials begin, helping the company align its development strategies with regulatory expectations regarding safety, tolerability, and non-clinical plans. The PEI's feedback provides early guidance on the company's biological rationale, safety assessments, and non-clinical development plan for its novel therapeutic platform. VERAXA believes this advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies.

The company's lead BiTAC®-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The BiTAC®-TCE platform is designed to engage T cells to attack cancer cells, and VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats.

The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer. The positive feedback from the PEI is a crucial step in de-risking the development pathway, potentially accelerating timelines for clinical entry. For more information on VERAXA Biotech and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA.

This development underscores VERAXA's commitment to rigorous regulatory engagement and its strategy to leverage scientific advice to optimize development plans. As the company moves forward, the guidance from PEI will inform key decisions in non-clinical studies and safety assessments, ultimately supporting the progression of its lead candidate toward clinical trials.